Integrating Biology And Medicine To Develop 3D-structure Guided Drug Design For Treatment Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$978,832.00
Summary
Calcium channel inhibitors are commonly prescribed for the treatment of heart disorders such as angina, hypertension, arrhythmias and hypertrophic heart disease. This class of drugs is one of the leading causes of drug-related fatalities. The impediment to designing better drugs is a lack of understanding of the 3 dimensional (3D) structure of the calcium channel. We will enable for the first time a 3D structure blueprint for the design of safe and highly selective calcium channel therapeutics.
Neural Circuits Which Limit Alcohol And Soft Drink Intake
Funder
National Health and Medical Research Council
Funding Amount
$523,949.00
Summary
Alcohol and soft drinks are ubiquitous, and often harmful, particularly in excess. This project will examine the specific roles of fluid and food satiation neural circuits in suppressing intake, to determine whether either or both could be therapeutic targets for alcohol/soft drink overconsumption, especially as cessation aids for binge-drinking behaviour.
A Cellular Identity Crisis: Deciphering How Mammary Epithelial Cells Form And Maintain Their Identity
Funder
National Health and Medical Research Council
Funding Amount
$843,826.00
Summary
The ability to regenerate human organs from adult cells efficiently and without error is a major goal of biomedical research in Australia, with significant economic benefits. As one of the most regenerative organs in a woman's body, the breast is an excellent model to study mechanisms that underpin tissue growth and regrowth. Moreover, as these pathways are often hijacked by cancer, this research has important implications for the development of new targeted therapies to treat breast cancer.
Interferon Epsilon As A Novel Regulator Of Host-bacterial Interaction In Homeostasis, Infection And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$843,088.00
Summary
Gut infections are a leading cause of death worldwide and healthcare use in Australia. Inflammatory bowel disease (IBD) is incurable and affects 1/200 young Australians. Type I interferons (T1IFNs) are important to control gut infections and IBD by interacting with particular bacterial species in the gut. We discovered one T1IFN, IFNε, in human gut. It protects against models of IBD in mice. We will use mouse and human samples to find bacterial or interferon treatments for infections and/or IBD.
Over 2 million Australians have diabetes and up to one in three adults will develop diabetes or pre-diabetes in their lifetime with the associated burden of complications. It is not simply genetics, as the genetic variability cannot explain why some individuals and indeed some families appear to be programmed to have an inordinate burden of complications. Over the last decade we have developed state of the art technologies to characterise epigenetic changes in human clinical cohorts.
Casting The Net: A New Approach To Identify Therapeutics To Treat Type-2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,068,283.00
Summary
The discovery of treatments for type-2 diabetes (T2D) is a national health priority. In T2D, cells in the brain become 'insulin resistant' resulting in dangerously high blood sugar levels. There are no treatments for brain insulin resistance. The extracellular structures that surround brain cells undergo change in T2D, resulting in insulin resistance. By furthering understanding of these extracellular brain structures, this proposal will identify new drug targets to treat T2D.
Preservation And Generation Of Beta Cells In Type 1 Diabetes With Novel Mimetic Peptides
Funder
National Health and Medical Research Council
Funding Amount
$1,096,055.00
Summary
Type 1 diabetes (T1D) is an autoimmune disease that destroys insulin producing beta cells in the pancreas. It can cause heart and kidney disease, and nerve damage. T1D is treated with insulin injections that can cause life-threatening low blood sugar levels. We have developed a new treatment that may stop beta cell loss, generate new beta cells and remove the need for insulin injections in T1D patients. A positive outcome will identify a completely new T1D treatment option.
Tolerising Antigen-specific Immunotherapy For Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,395,549.00
Summary
We have developed a new immunotherapy to treat the underlying causes of type 1 diabetes (T1D) while leaving the rest of the immune system intact. To use this in patients, we need better tests to know when immune therapy is working. We will develop new methods to design the therapy and tools to track the relevant immune cells in T1D that work in variable patient groups. The knowledge gained will speed the pace of development and increase the chance of success of immunotherapy in T1D.